-
Reply: Asthma and cardiovascular disease: the strength of triangulation Eur. Respir. J. (IF 24.3) Pub Date : 2024-04-25 Chloe I. Bloom
Extract In their correspondence, M.C. Tattersall and co-workers noted that our study reports contrasting findings to some earlier studies, including their own. They have raised several methodological points regarding our triangulation approach which leveraged two wholly different methods (traditional observational study and Mendelian randomisation) and multiple entirely different datasets [1]. We have
-
Asthma and cardiovascular disease: embracing disease heterogeneity is required Eur. Respir. J. (IF 24.3) Pub Date : 2024-04-25 Matthew C. Tattersall, Ronald E. Gangnon, Nizar N. Jarjour
Extract We read with interest the recent original research investigation by Valencia-Hernández et al. [1]. This observational study used two approaches to investigate the association of asthma and coronary heart disease (CHD): medical records and Mendelian randomisation (MR). Their results differ compared to many other prior studies investigating the association of asthma and CHD [2]. We applaud the
-
B-cells in pulmonary arterial hypertension: friend, foe or bystander? Eur. Respir. J. (IF 24.3) Pub Date : 2024-04-25 Sébastien Sanges, Wen Tian, Sylvain Dubucquoi, Jason L. Chang, Aurore Collet, David Launay, Mark R. Nicolls
There is an unmet need for new therapeutic strategies that target alternative pathways to improve the prognosis of patients with pulmonary arterial hypertension (PAH). As immunity has been involved in the development and progression of vascular lesions in PAH, we review the potential contribution of B-cells in its pathogenesis and evaluate the relevance of B-cell-targeted therapies. Circulating B-cell
-
Early life exposure to pollens and increased risks of childhood asthma: a prospective cohort study in Ontario children Eur. Respir. J. (IF 24.3) Pub Date : 2024-04-18 Cristina Stanescu, Robert Talarico, Scott Weichenthal, Paul J. Villeneuve, Audrey Smargiassi, David M. Stieb, Teresa To, Christopher Hebbern, Eric Crighton, Éric Lavigne
Extract Asthma is a disease characterised by wheeze, cough and shortness of breath, and constitutes the most prevalent chronic disease among children [1]. Various phenotypes have been specifically identified in the paediatric population, and include early transient wheeze, current wheeze/asthma, and mild or moderate asthma [2]. Lifestyle behaviours, genetics, maternal and paternal factors, and environment
-
ERJ Podcast April 2024: Allergic bronchopulmonary aspergillosis Eur. Respir. J. (IF 24.3) Pub Date : 2024-04-18 European Respiratory Society
As part of the April issue, the European Respiratory Journal presents the latest in its series of podcasts. Chief Editor James Chalmers interviews Ritesh Agarwal (Department of Pulmonary Medicine, Postgraduate Institute of Medical Education and Research, Chandigarh, India) about the revised International Society for Human and Animal Mycology ABPA working group clinical practice guidelines for diagnosing
-
“Therapeutic improvement of CFTR function and reversibility of bronchiectasis in cystic fibrosis.” M.O. Wielpütz and M.A. Mall. Eur Respir J 2024; 63: 2400234. Eur. Respir. J. (IF 24.3) Pub Date : 2024-04-18 European Respiratory Society
In this article, the PRAGMA-CF scoring system was incorrectly referred to as the “PRAGA-CF scoring …
-
Smoking cessation at lung cancer screening: joining (life-saving) dots Eur. Respir. J. (IF 24.3) Pub Date : 2024-04-18 Keir E. Lewis
Extract We now know that lung cancer screening with low-dose computed tomography saves lives. We have known for more than 60 years that smoking cessation (SC) saves lives. Can we save even more lives by combining these two effective interventions? The work by Murray et al. [1], in this issue of the European Respiratory Journal, is a big stride to show that we can.
-
Precision medicine in cystic fibrosis: predictive role of forskolin-induced swelling assay Eur. Respir. J. (IF 24.3) Pub Date : 2024-04-18 Eva Furstova, Pavel Drevinek, Stepanka Novotna, Malgorzata Libik, Klara Benesova, Lucie Borek-Dohalska, Kristina Sakmarova, Martin Modrak, Milan Macek, Tereza Dousova
Extract People with cystic fibrosis (CF) carrying at least one copy of the F508del allele can benefit from a small molecule therapy referred to as cystic fibrosis transmembrane conductance regulator (CFTR) modulators (CFTRm). The triple CFTRm combination elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) has been shown to markedly improve clinical outcomes such as the percentage of predicted forced expiratory
-
Sputum colour as a simplified effective biomarker for clinical assessment of bronchiectasis Eur. Respir. J. (IF 24.3) Pub Date : 2024-04-18 Rui-di Tang, Jun-qing Yue, Wei-jie Guan
Extract Bronchiectasis is a structural lung disease characterised by chronic airway inflammation due to various aetiologies, with a vicious circle of recurrent infections, chronic inflammation, impaired mucociliary clearance and structural damage that collectively result in clinical progression [1]. The most prominent clinical manifestations of bronchiectasis are chronic cough and mucopurulent sputum
-
Impact of obesity progression or regression on the longitudinal assessment of fibrosing interstitial lung disease Eur. Respir. J. (IF 24.3) Pub Date : 2024-04-18 Hadeel Alqurashi, Mathieu Marillier, Igor Neder-Serafini, Anne-Catherine Bernard, Onofre Moran-Mendoza, J. Alberto Neder
Extract Abnormalities in lung mechanics (restriction) and pulmonary gas exchange (hypoxaemia) may jointly conspire to elicit exertional dyspnoea and decrease exercise tolerance in patients with fibrosing interstitial lung disease (f-ILD) [1]. Obesity (body mass index (BMI) ≥30 kg·m–2), a prevalent comorbidity of f-ILD [2], may negatively impact on "static" (e.g. total lung capacity (TLC)) and dynamic
-
Uptake and 4-week quit rates from an opt-out co-located smoking cessation service delivered alongside community-based low-dose computed tomography screening within the Yorkshire Lung Screening Trial Eur. Respir. J. (IF 24.3) Pub Date : 2024-04-18 Rachael L. Murray, Panos Alexandris, David Baldwin, Kate Brain, John Britton, Philip A.J. Crosbie, Rhian Gabe, Sarah Lewis, Steve Parrott, Samantha L. Quaife, Hui Zhen Tam, Qi Wu, Rebecca Beeken, Harriet Copeland, Claire Eckert, Neil Hancock, Jason Lindop, Grace McCutchan, Catriona Marshall, Richard D. Neal, Suzanne Rogerson, Harriet D. Quinn Scoggins, Irene Simmonds, Rebecca Thorley, Matthew E. Callister
Extract Low-dose computed tomography (LDCT) screening for lung cancer has been shown to reduce lung cancer-specific mortality in two large, randomised trials [1, 2], and implementation of screening is currently underway in many high- and middle-income countries [3]. Of those people responding to an invitation for lung cancer screening and subsequently eligible, between 30% and 50% are currently smoking
-
Airway remodelling in asthma and the epithelium: on the edge of a new era Eur. Respir. J. (IF 24.3) Pub Date : 2024-04-18 Gilda Varricchi, Christopher E. Brightling, Christopher Grainge, Bart N. Lambrecht, Pascal Chanez
Asthma is a chronic, heterogeneous disease of the airways, often characterised by structural changes known collectively as airway remodelling. In response to environmental insults, including pathogens, allergens and pollutants, the epithelium can initiate remodelling via an inflammatory cascade involving a variety of mediators that have downstream effects on both structural and immune cells. These
-
Objective sputum colour assessment and clinical outcomes in bronchiectasis: data from the European Bronchiectasis Registry (EMBARC) Eur. Respir. J. (IF 24.3) Pub Date : 2024-04-18 Stefano Aliberti, Felix C. Ringshausen, Raja Dhar, Charles S. Haworth, Michael R. Loebinger, Katerina Dimakou, Megan L. Crichton, Anthony De Soyza, Montse Vendrell, Pierre-Regis Burgel, Melissa McDonnell, Sabina Skrgat, Luis Maiz Carro, Andres de Roux, Oriol Sibila, Apostolos Bossios, Menno van der Eerden, Paula Kauppi, Robert Wilson, Branislava Milenkovic, Rosario Menendez, Marlene Murris, Sermin
Extract Bronchiectasis is a chronic inflammatory disease [1, 2]. Although it is recognised that bronchiectasis is composed of multiple phenotypes and endotypes, inflammation has classically been regarded as neutrophilic and patients with higher levels of neutrophilic inflammation have been shown to have worse clinical outcomes [3–5].
-
“Efficacy and safety of ralinepag, a novel oral IP agonist, in PAH patients on mono or dual background therapy: results from a phase 2 randomised, parallel group, placebo-controlled trial.” F. Torres, H. Farber, A. Ristic, et al. Eur Respir J 2019; 54: 1901030. Eur. Respir. J. (IF 24.3) Pub Date : 2024-04-18 European Respiratory Society
In table 1 of this article, the data relating …
-
Response from the authors: As-needed ICS/formoterol or as-needed SABA in mild asthma? Eur. Respir. J. (IF 24.3) Pub Date : 2024-04-04 Alberto Papi, Diogenes S. Ferreira, Thomy Tonia, Florence Schleich
Extract We thank J.A. Krishnan and R. Buhl for their commentary on our document "European Respiratory Society short guidelines for the use of as-needed ICS/formoterol in mild asthma", which was published in this journal in October 2023 [1]. We appreciate their willingness in building trust in the guideline development process.
-
FEV1Q: what (even) is normal lung function? Eur. Respir. J. (IF 24.3) Pub Date : 2024-04-04 Arafa Aboelhassan, John R. Hurst
Extract People come in different shapes and sizes, and so do their lungs. This seemingly trivial observation raises significant problems when it comes to defining the presence and severity of lung function impairment using spirometry – a fundamental test in respiratory physiology. A common approach is to make a lung function measurement such as forced expiratory volume in 1 s (FEV1), and to compare
-
Combined pulmonary fibrosis and emphysema syndrome: the age of majority Eur. Respir. J. (IF 24.3) Pub Date : 2024-04-04 Vincent Cottin
Extract Described in 1990, the combination of pulmonary fibrosis and emphysema is associated with a distinctive physiological profile, with preserved lung volumes and airflow, and severely altered diffusion capacity for carbon monoxide (DLCO) [1]. Combined pulmonary fibrosis and emphysema (CPFE) was individualised as a syndrome in 2005 in a series of 61 patients [2], which drew attention to its main
-
Dysfunctional breathing after COVID-19: recognition and ramifications Eur. Respir. J. (IF 24.3) Pub Date : 2024-04-04 Adam Gaffney
Extract Protracted breathlessness in the wake of a COVID-19 infection is the consequence not of one disease process but many. COVID-19 pneumonia can severely damage lung architecture, with resultant long-term reductions in respiratory function, gas exchange and exercise capacity: a pattern of injury few respiratory physicians would fail to recognise. A more diagnostically challenging presentation can
-
Availability of paediatric dispersible fixed-dose combinations of tuberculosis drugs in Spain Eur. Respir. J. (IF 24.3) Pub Date : 2024-04-04 Antoni Noguera-Julian, Cristina Latre, Ángeles Flores
Extract We read with interest the viewpoint on tuberculosis (TB) elimination recently published in the European Respiratory Journal [1]. The correct treatment of children is essential to ensure future TB-free generations [2, 3]. The paediatric dispersible fixed-dose combination tablets (pFDC) of first-line anti-TB drugs were first made available in 2015, are World Health Organization (WHO)-prequalified
-
Revised ISHAM-ABPA working group clinical practice guidelines for diagnosing, classifying and treating allergic bronchopulmonary aspergillosis/mycoses Eur. Respir. J. (IF 24.3) Pub Date : 2024-04-04 Ritesh Agarwal, Inderpaul Singh Sehgal, Valliappan Muthu, David W. Denning, Arunaloke Chakrabarti, Kathirvel Soundappan, Mandeep Garg, Shivaprakash M. Rudramurthy, Sahajal Dhooria, Darius Armstrong-James, Koichiro Asano, Jean-Pierre Gangneux, Sanjay H. Chotirmall, Helmut J.F. Salzer, James D. Chalmers, Cendrine Godet, Marcus Joest, Iain Page, Parameswaran Nair, P. Arjun, Raja Dhar, Kana Ram Jat, Geethu
Background The International Society for Human and Animal Mycology (ISHAM) working group proposed recommendations for managing allergic bronchopulmonary aspergillosis (ABPA) a decade ago. There is a need to update these recommendations due to advances in diagnostics and therapeutics. Methods An international expert group was convened to develop guidelines for managing ABPA (caused by Aspergillus spp
-
As-needed ICS/formoterol or as-needed SABA in mild asthma? Eur. Respir. J. (IF 24.3) Pub Date : 2024-04-04 Jerry A. Krishnan, Roland Buhl
Extract The majority of people with asthma are believed to have "mild" asthma [1]. The term "mild asthma" is usually used to define patients with infrequent or easily relieved respiratory symptoms. However, patients with mild asthma can have severe exacerbations, which, in rare cases, lead to death. The bronchodilatory effects of inhaled short-acting β2-agonists (SABAs) help to provide rapid respiratory
-
Multi-biobank summary data Mendelian randomisation does not support a causal effect of IL-6 signalling on risk of pulmonary arterial hypertension Eur. Respir. J. (IF 24.3) Pub Date : 2024-04-04 Woolf, B., Perry, J. A., Hong, C. C., Wilkins, M. R., Toshner, M., Gill, D., Burgess, S., Rhodes, C. J.
Extract Interleukin (IL)-6 has been linked with the pathobiology of pulmonary arterial hypertension (PAH). IL-6 plasma levels are elevated in PAH patients and closely linked to survival [1]. Both increased IL-6 activity and gene knockout influence the development of, and resistance to, pulmonary hypertension in animal models [2–4]. IL-6 can repress expression of BMPR2, a gene key in PAH risk [5].
-
Pulmonary vascular phenotype identified in patients with GDF2 (BMP9) or BMP10 variants: an international multicentre study Eur. Respir. J. (IF 24.3) Pub Date : 2024-04-04 Julien Grynblat, Harm Jan Bogaard, Mélanie Eyries, Olivier Meyrignac, Laurent Savale, Xavier Jaïs, Maria-Rosa Ghigna, Lucas Celant, Lilian Meijboom, Arjan C. Houweling, Marilyne Levy, Fabrice Antigny, Ari Chaouat, Vincent Cottin, Christophe Guignabert, Florence Coulet, Olivier Sitbon, Damien Bonnet, Marc Humbert, David Montani
Background Bone morphogenetic proteins 9 and 10 (BMP9 and BMP10), encoded by GDF2 and BMP10, respectively, play a pivotal role in pulmonary vascular regulation. GDF2 variants have been reported in pulmonary arterial hypertension (PAH) and hereditary haemorrhagic telangiectasia (HHT). However, the phenotype of GDF2 and BMP10 carriers remains largely unexplored. Methods We report the characteristics
-
FEV1Q: a race-neutral approach to assessing lung function Eur. Respir. J. (IF 24.3) Pub Date : 2024-04-04 Balasubramanian, A., Wise, R. A., Stanojevic, S., Miller, M. R., McCormack, M. C.
Background Forced expiratory volume in 1 s quotient (FEV1Q) is a simple approach to spirometry interpretation that compares measured lung function to a lower boundary. This study evaluated how well FEV1Q predicts survival compared with current interpretation methods and whether race impacts FEV1Q. Methods White and Black adults with complete spirometry and mortality data from the National Health and
-
The airway epithelium: an orchestrator of inflammation, a key structural barrier and a therapeutic target in severe asthma Eur. Respir. J. (IF 24.3) Pub Date : 2024-04-04 Russell, R. J., Boulet, L.-P., Brightling, C. E., Pavord, I. D., Porsbjerg, C., Dorscheid, D., Sverrild, A.
Asthma is a disease of heterogeneous pathology, typically characterised by excessive inflammatory and bronchoconstrictor responses to the environment. The clinical expression of the disease is a consequence of the interaction between environmental factors and host factors over time, including genetic susceptibility, immune dysregulation and airway remodelling. As a critical interface between the host
-
Mortality surrogates in combined pulmonary fibrosis and emphysema Eur. Respir. J. (IF 24.3) Pub Date : 2024-04-04 An Zhao, Eyjolfur Gudmundsson, Nesrin Mogulkoc, Coline van Moorsel, Tamera J. Corte, Pardeep Vasudev, Chiara Romei, Robert Chapman, Tim J.M. Wallis, Emma Denneny, Tinne Goos, Recep Savas, Asia Ahmed, Christopher J. Brereton, Hendrik W. van Es, Helen Jo, Annalisa De Liperi, Mark Duncan, Katarina Pontoppidan, Laurens J. De Sadeleer, Frouke van Beek, Joseph Barnett, Gary Cross, Alex Procter, Marcel Veltkamp
Extract Emphysema is a common pulmonary finding on computed tomography (CT) imaging of idiopathic pulmonary fibrosis (IPF) patients [1]. The term combined pulmonary fibrosis and emphysema (CPFE) describes a potential clinical endotype characterised by the coexistence of upper-lobe-predominant emphysema, lower-lobe-predominant fibrosis and relative preservation of forced vital capacity (FVC) in the
-
Lung MRI identifies potentially treatable subtypes of long COVID Eur. Respir. J. (IF 24.3) Pub Date : 2024-03-28 Alejandro P. Comellas, Sean B. Fain
Extract The coronavirus disease 2019 (COVID-19) pandemic affected millions and left an indelible mark on global health. Although many patients have recovered from acute severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, 21–50% continue to experience persistent symptoms beyond their initial infection [1, 2]. This wide range in estimate depends on variables such as patient demographics
-
Therapeutic improvement of CFTR function and reversibility of bronchiectasis in cystic fibrosis Eur. Respir. J. (IF 24.3) Pub Date : 2024-03-28 Mark O. Wielpütz, Marcus A. Mall
Extract By rule of thumb, the diameter of intrapulmonary subsegmental bronchi is increased if larger than the adjacent pulmonary artery at cross-sectional imaging such as computed tomography (CT), coining the definition of bronchiectasis. This definition, however, is limited by the fact that the artery itself is subject to diameter changes in airways and vascular pulmonary diseases, which also affect
-
“Asthma and incident coronary heart disease: an observational and Mendelian randomisation study.” C.A. Valencia-Hernández, F. Del Greco M, V. Sundaram, et al. Eur Respir J 2023; 62: 2301788. Eur. Respir. J. (IF 24.3) Pub Date : 2024-03-28 European Respiratory Society
In this article, the protocol number for …
-
Cluster analysis to identify long COVID phenotypes using 129Xe magnetic resonance imaging: a multicentre evaluation Eur. Respir. J. (IF 24.3) Pub Date : 2024-03-28 Eddy, R. L., Mummy, D., Zhang, S., Dai, H., Bechtel, A., Schmidt, A., Frizzell, B., Gerayeli, F. V., Leipsic, J. A., Leung, J. M., Driehuys, B., Que, L. G., Castro, M., Sin, D. D., Niedbalski, P. J.
Background Long COVID impacts ~10% of people diagnosed with coronavirus disease 2019 (COVID-19), yet the pathophysiology driving ongoing symptoms is poorly understood. We hypothesised that 129Xe magnetic resonance imaging (MRI) could identify unique pulmonary phenotypic subgroups of long COVID. Therefore, we evaluated ventilation and gas exchange measurements with cluster analysis to generate imaging-based
-
Reversal of cylindrical bronchial dilatations in a subset of adults with cystic fibrosis treated with elexacaftor/tezacaftor/ivacaftor Eur. Respir. J. (IF 24.3) Pub Date : 2024-03-28 Paul Cazier, Guillaume Chassagnon, Théo Dhote, Jennifer Da Silva, Reem Kanaan, Isabelle Honoré, Nicolas Carlier, Marie-Pierre Revel, Emma Canniff, Clémence Martin, Pierre-Régis Burgel
Background This study sought to evaluate the impact of elexacaftor/tezacaftor/ivacaftor (ETI) on lung structural abnormalities in adults with cystic fibrosis (awCF) with a specific focus on the reversal of bronchial dilatations. Methods Chest computed tomography (CT) scans performed prior to and 12 months after initiation of ETI were visually reviewed for possible reversal of bronchial dilatations
-
ERS/EBMT clinical practice guidelines on treatment of pulmonary chronic graft-versus-host disease in adults Eur. Respir. J. (IF 24.3) Pub Date : 2024-03-28 Saskia Bos, John Murray, Monia Marchetti, Guang-Shing Cheng, Anne Bergeron, Daniel Wolff, Clare Sander, Akshay Sharma, Sherif M. Badawy, Zinaida Peric, Agnieszka Piekarska, Joseph Pidala, Kavita Raj, Olaf Penack, Samar Kulkarni, Molly Beestrum, Andrea Linke, Matthew Rutter, Courtney Coleman, Thomy Tonia, Hélène Schoemans, Daiana Stolz, Robin Vos
Chronic graft-versus-host disease (cGvHD) is a common complication after allogeneic haematopoietic stem cell transplantation, characterised by a broad disease spectrum that can affect virtually any organ. Although pulmonary cGvHD is a less common manifestation, it is of great concern due to its severity and poor prognosis. Optimal management of patients with pulmonary cGvHD is complicated and no standardised
-
Pulmonary phase contrast CT imaging: a novel setup at the Italian synchrotron for the study of fresh lungs at human scale Eur. Respir. J. (IF 24.3) Pub Date : 2024-03-28 Dullin, C., Wagner, W. L., Confalonieri, M., Tromba, G.
Extract High-resolution computed tomography (HRCT) remains the current gold standard for detailed morphological assessment of the human lung, but is intrinsically limited in spatial resolution to about 0.5 mm, because an increase in spatial resolution is accompanied by a significant increase in the required radiation dose.
-
ERJ Podcast March 2024: Long COVID Eur. Respir. J. (IF 24.3) Pub Date : 2024-03-28 European Respiratory Society
As part of the March issue, the European Respiratory Journal presents the latest in its series of podcasts. Deputy Chief Editor Don Sin interviews Associate Editor Joan Soriano about long COVID, which is the subject of a series of articles in the March and April issues of the ERJ.
-
Systematic pulmonary embolism follow-up: why we should all do it! Eur. Respir. J. (IF 24.3) Pub Date : 2024-03-14 Luke S. Howard, Laura C. Price
Extract For many years now, the pulmonary hypertension community has been trying to narrow down on the true incidence of chronic thromboembolic pulmonary hypertension (CTEPH) following pulmonary embolism. The study by Durrington et al. [1] in this issue of the European Respiratory Journal undoubtedly gets us closer, suggesting a cumulative incidence of 2.1%; however, with 41% of the entire post-pulmonary
-
Reply to: Insights on the ERS/ESTS statement on the management of pleural infection in adults Eur. Respir. J. (IF 24.3) Pub Date : 2024-03-14 Eihab O. Bedawi, Najib M. Rahman
Extract We thank Y. Li and co-workers for their interest in the European Respiratory Society/European Society of Thoracic Surgeons statement on the management of pleural infection, recently published in the European Respiratory Journal [1]. Our interpretation of their correspondence is that they have misunderstood "IPC" to denote a standard chest drain or tube used, with a well-established evidence
-
Insights on the ERS/ESTS statement on the management of pleural infection in adults Eur. Respir. J. (IF 24.3) Pub Date : 2024-03-14 Yalun Li, Hao Zeng, Panwen Tian, Weimin Li
Extract We read with great interest the article by Bedawi et al. [1], recently published in the prestigious European Respiratory Journal, on the management of pleural infection in adults. We highly commend this work and here we wish to focus on the management of pleural infection with indwelling pleural catheters (IPC). The statement suggested that recurrent or chronic pleural infection created difficult
-
Haemodynamic phenotypes of pulmonary hypertension associated with left heart disease: a moving target Eur. Respir. J. (IF 24.3) Pub Date : 2024-03-14 Christian Gerges, David Montani, Marc Humbert, Irene M. Lang
Shifting haemodynamic definitions impact prevalence of CpcPH in PH associated with left heart disease. Diastolic pressure gradient ≥7 mmHg and pulmonary vascular resistance >5 WU predict pulmonary vascular disease similarly well.
-
Core outcome measurement set for research and clinical practice in post-COVID-19 condition (long COVID) in children and young people: an international Delphi consensus study “PC-COS Children” Eur. Respir. J. (IF 24.3) Pub Date : 2024-03-14 Nina Seylanova, Anastasia Chernyavskaya, Natalia Degtyareva, Aigun Mursalova, Ali Ajam, Lin Xiao, Khazhar Aktulaeva, Philipp Roshchin, Polina Bobkova, Olalekan Lee Aiyegbusi, Anbarasu Theodore Anbu, Christian Apfelbacher, Ali Akbar Asadi-Pooya, Liat Ashkenazi-Hoffnung, Caroline Brackel, Danilo Buonsenso, Wouter de Groote, Janet V. Diaz, Daniele Dona, Audrey Dunn Galvin, Jon Genuneit, Helen Goss, Sarah
The coronavirus disease 2019 (COVID-19) pandemic substantially impacted different age groups, with children and young people not exempted. Many have experienced enduring health consequences. Presently, there is no consensus on the health outcomes to assess in children and young people with post-COVID-19 condition. Furthermore, it is unclear which measurement instruments are appropriate for use in research
-
Systematic pulmonary embolism follow-up increases diagnostic rates of chronic thromboembolic pulmonary hypertension and identifies less severe disease: results from the ASPIRE Registry Eur. Respir. J. (IF 24.3) Pub Date : 2024-03-14 Charlotte Durrington, Judith A. Hurdman, Charlie A. Elliot, Rhona Maclean, Joost Van Veen, Giorgia Saccullo, Duneesha De-Foneska, Andrew J. Swift, Rajaram Smitha, Catherine Hill, Steven Thomas, Krit Dwivedi, Samer Alabed, James M. Wild, Athanasios Charalampopoulos, Abdul Hameed, Alexander M.K. Rothman, Lisa Watson, Neil Hamilton, A.A. Roger Thompson, Robin Condliffe, David G. Kiely
Extract Pulmonary embolism (PE) is a condition in which thrombus, usually embolised from the veins of the pelvis or lower limbs, obstructs the pulmonary arterial vascular bed. The incidence of PE is estimated at 60–70 per 100 000 per year [1] with a 1-year mortality of 15% [2, 3]. In survivors, patency of the pulmonary vasculature is restored, in most patients, within the first few months [4]. However
-
Socioeconomic disparities in European cystic fibrosis outcomes: time to close the gap Eur. Respir. J. (IF 24.3) Pub Date : 2024-03-07 Edward F. McKone
Extract Cystic fibrosis (CF) is one of the most common autosomal recessive genetic conditions that causes progressive lung disease and premature death [1]. Median survival worldwide is estimated to be around 50 years, but there is variation between countries [2–4]. Reasons for this variation are complex, and include genetic factors such as cystic fibrosis transmembrane conductance regulator (CFTR)
-
Some future directions for genome-wide association studies of preserved ratio impaired spirometry Eur. Respir. J. (IF 24.3) Pub Date : 2024-03-07 Zhou Jin, Guangfa Wang
Extract We read with interest the paper by Higbee et al. [1] that was recently published in the European Respiratory Journal. They discovered 22 single nucleotide polymorphisms (SNPs) associated with preserved ratio impaired spirometry (PRISm) through a two-stage sample population, four of which were associated with lung function, highlighting the usefulness of performing genome-wide association study
-
Omics-based profiles and biomarkers of respiratory infections: are we there yet? Eur. Respir. J. (IF 24.3) Pub Date : 2024-03-07 Jezreel Pantaleon Garcia, Scott E. Evans
Extract From the influenza pandemic of 1918–1919 to the most recent COVID-19 pandemic, respiratory infections remain a leading cause of mortality worldwide [1, 2]. Concurrently, the development of high-throughput omics technologies has revolutionised research about host responses to known and emerging respiratory pathogens [3], accelerating our understanding of highly prevalent pulmonary diseases [4]
-
High altitude travelling with pulmonary arterial hypertension Eur. Respir. J. (IF 24.3) Pub Date : 2024-03-07 Robert Naeije
Extract Altitude exposure is generally considered to be contraindicated in pulmonary arterial hypertension (PAH), out of concern that (hypobaric) hypoxic pulmonary vasoconstriction (HPV) might further increase pulmonary vascular resistance (PVR) and worsen right heart failure [1]. This notion is mentioned in the guidelines of the European Society of Cardiology (ESC) and European Respiratory Society
-
Endotypic traits of supine position and supine-predominant obstructive sleep apnoea in Asian patients Eur. Respir. J. (IF 24.3) Pub Date : 2024-03-07 Cheng, W.-J., Finnsson, E., Agustsson, J. S., Sands, S. A., Hang, L.-W.
Background Over half of all cases of obstructive sleep apnoea (OSA) are classified as supine-related OSA; however, the pathological endotype during supine position is not fully understood. This study aims to investigate the endotypic traits of supine-predominant OSA and explore the variations in endotypic traits between the supine and lateral positions. Methods We prospectively recruited 689 adult
-
Neutrophil elastase-dependent cleavage of LTA4H alters its aminopeptidase activity in cystic fibrosis Eur. Respir. J. (IF 24.3) Pub Date : 2024-03-07 Xin Xu, Jin-dong Li, Todd J. Green, Landon Wilson, Kristopher Genschmer, Derek Russell, J. Edwin Blalock, Amit Gaggar
Extract The enzyme leukotriene A4 hydrolase (LTA4H) is classically known for its epoxide hydrolase activity that converts leukotriene A4 (LTA4) to the neutrophil chemoattractant LTB4 [1]. In 2010, our group published a study in Science that demonstrated that during an influenza model of acute airway inflammation, LTA4H was released from cells to degrade proline-glycine-proline (PGP), a non-canonical
-
Cystic fibrosis in Europe: improved lung function and longevity – reasons for cautious optimism, but challenges remain Eur. Respir. J. (IF 24.3) Pub Date : 2024-03-07 Eitan Kerem, Annalisa Orenti, Arianna Adamoli, Elpis Hatziagorou, Lutz Naehrlich, Isabelle Sermet-Gaudelus
Background Prognosis and disease severity in cystic fibrosis (CF) are linked to declining lung function. To characterise lung function by the number of adults in countries with different levels of Gross National Income (GNI), data from the European Cystic Fibrosis Society Patient Registry were utilised. Methods Annual data including age, forced expiratory volume in 1 s (FEV1), anthropometry, genotype
-
The effect of high altitude (2500 m) on incremental cycling exercise in patients with pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: a randomised controlled crossover trial Eur. Respir. J. (IF 24.3) Pub Date : 2024-03-07 Julian Müller, Anna Titz, Simon R. Schneider, Meret Bauer, Laura Mayer, Lea Lüönd, Tanja Ulrich, Michael Furian, Aglaia Forrer, Esther I. Schwarz, Konrad E. Bloch, Mona Lichtblau, Silvia Ulrich
Background Our objective was to investigate the effect of a day-long exposure to high altitude on peak exercise capacity and safety in stable patients with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH). Methods In a randomised controlled crossover trial, stable patients with PAH or distal CTEPH without resting hypoxaemia at low altitude performed two
-
Extensive acute and sustained changes to neutrophil proteomes post-SARS-CoV-2 infection Eur. Respir. J. (IF 24.3) Pub Date : 2024-03-07 Merete B. Long, Andrew J.M. Howden, Holly R. Keir, Christina M. Rollings, Yan Hui Giam, Thomas Pembridge, Lilia Delgado, Hani Abo-Leyah, Amy F. Lloyd, Gabriel Sollberger, Rebecca Hull, Amy Gilmour, Chloe Hughes, Benjamin J.M. New, Diane Cassidy, Amelia Shoemark, Hollian Richardson, Angus I. Lamond, Doreen A. Cantrell, James D. Chalmers, Alejandro J. Brenes
Background Neutrophils are important in the pathophysiology of coronavirus disease 2019 (COVID-19), but the molecular changes contributing to altered neutrophil phenotypes following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are not fully understood. We used quantitative mass spectrometry-based proteomics to explore neutrophil phenotypes immediately following acute SARS-CoV-2
-
Reply to: Supporting the case for a targeted approach for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with no F508del CFTR variant: further analysis for the French compassionate use programme Eur. Respir. J. (IF 24.3) Pub Date : 2024-02-29 Pierre-Régis Burgel
Extract In their correspondence, M. Dooney and T. Saba propose further analysis of the recently published data originating from the French compassionate programme for elexacaftor/tezacaftor/ivacaftor (ETI) in people with cystic fibrosis (CF) and no F508del variant [1]. They suggest that ETI eligibility criteria should be based on the absence of "known to be unresponsive" variants rather than on the
-
“Age-related changes in plasma biomarkers and their association with mortality in COVID-19.” E.H.A. Michels, B. Appelman, J. de Brabander, et al. Eur Respir J 2023; 62: 2300011. Eur. Respir. J. (IF 24.3) Pub Date : 2024-02-29 European Respiratory Society
While drafting a follow-up manuscript to this article – in which the mediation analysis will be validated using data from a randomised controlled trial – the authors noted an error in the research article as originally published in the European Respiratory Journal . The error pertains to the spline model used in calculating the odds ratio for age-related mortality, as illustrated in figures 2b and
-
Interalveolar pore morphology in (pre-)COPD stages and associations with small airways Eur. Respir. J. (IF 24.3) Pub Date : 2024-02-29 Stijn E. Verleden, Therese S. Lapperre, Annemiek Snoeckx, Wen Wen, Suresh K. Yogeswaran, Geert M. Verleden, Veronique Verplancke, Reinier R.L. Wener, Senada Koljenovic, Dieter J.E. Peeters, Jeroen M.H. Hendriks
Extract COPD is nowadays considered to be a heterogeneous lung condition characterised by chronic respiratory symptoms caused by airway and/or alveolar abnormalities causing persistent airflow obstruction. This airflow obstruction is defined by a post-bronchodilator forced expiratory volume in 1 s (FEV1) to forced vital capacity (FVC) ratio lower than 0.7. However, the recent 2023 Global Initiative
-
Lung transcriptome of e-cigarette users reveals changes related to chronic lung disease Eur. Respir. J. (IF 24.3) Pub Date : 2024-02-29 Kidane, B., Kahnamoui, S., Srinathan, S., Liu, R., Tan, L., Morris, M., Shawyer, A., Halayko, A. J., Pascoe, C. D.
Extract Approximately one in 10 adolescents use e-cigarette devices, with 25% of these reporting daily use [1]. Most youth who vape have never used traditional cigarettes, creating an emerging epidemic of nicotine addiction fuelled by use of e-cigarettes [2]. Public perception is that e-cigarettes are less harmful than traditional cigarettes, a belief that may be fuelled, in part, by a handful of tobacco
-
Supporting the case for a targeted approach for elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis with no F508del CFTR variant: further analysis for the French compassionate use programme Eur. Respir. J. (IF 24.3) Pub Date : 2024-02-29 Dooney, M., Saba, T.
Extract We have read with great interest the work of Burgel et al. [1] and applaud them for their innovative use of elexacaftor/tezacaftor/ivacaftor (ETI) in combination with ivacaftor (IVA) in people with significant cystic fibrosis (CF) respiratory disease who were carriers of cystic fibrosis transmembrane conductance regulator (CFTR) variants that did not meet eligibility criteria for funded treatment
-
ERJ Podcast February 2024: Beetroot juice and cardiovascular risk in COPD Eur. Respir. J. (IF 24.3) Pub Date : 2024-02-29 European Respiratory Society
As part of the February issue, the European Respiratory Journal presents the latest in its series of podcasts. Deputy Chief Editor Don Sin interviews Nick Hopkinson about his study that shows consumption of nitrate-rich beetroot juice reduces cardiovascular risk factors in people living with COPD.
-
Unravelling the “frequent exacerbator” phenotype in cystic fibrosis Eur. Respir. J. (IF 24.3) Pub Date : 2024-02-22 Raya Cohen, Michal Shteinberg
Extract Exacerbations of chronic airway disease are well-described phenomena across diseases, including bronchiectasis (BE), whether secondary to cystic fibrosis (CF) or not. Exacerbations are frequent in CF and BE: in recent registries, 20% of children and 70% of adults with CF [1] and 75% of adults with BE [2] experienced at least one exacerbation in the previous year. In most diseases, the diagnosis
-
Understanding the clinical implications of the "non-classical" microbiome in chronic lung disease: a viewpoint Eur. Respir. J. (IF 24.3) Pub Date : 2024-02-22 Taylor, S. L., Crabbe, A., Hoffman, L. R., Chalmers, J. D., Rogers, G. B.
Extract In the late 1990s, molecular microbial system analytics started to be adapted and applied to chronic lung disease [1, 2]. These approaches revealed microbial diversity in respiratory samples that included many bacterial species more usually associated with the oropharynx (box 1 and figure 1). While contamination of samples by oropharyngeal microbes might account for a portion of these taxa
-
European Respiratory Society statement on novel nicotine and tobacco products, their role in tobacco control and “harm reduction” Eur. Respir. J. (IF 24.3) Pub Date : 2024-02-22 Daniel Tzu-Hsuan Chen, Jonathan Grigg, Filippos T. Filippidis
Extract A growing number of new tobacco and nicotine products have emerged in recent years and are especially popular among adolescents and young adults. These are collectively known as "novel and emerging nicotine and tobacco products" [1, 2], and include electronic cigarettes, heated tobacco products and nicotine pouches.
-
Associations of combined phenotypic ageing and genetic risk with incidence of chronic respiratory diseases in the UK Biobank: a prospective cohort study Eur. Respir. J. (IF 24.3) Pub Date : 2024-02-22 Wang, T., Duan, W., Jia, X., Huang, X., Liu, Y., Meng, F., Ni, C.
Background Accelerated biological ageing has been associated with an increased risk of several chronic respiratory diseases. However, the associations between phenotypic age, a new biological age indicator based on clinical chemistry biomarkers, and common chronic respiratory diseases have not been evaluated. Methods We analysed data from 308 592 participants at baseline in the UK Biobank. The phenotypic
-
Travel-acquired paediatric tuberculosis in the Greater Toronto Area, Canada, 2002–2018 Eur. Respir. J. (IF 24.3) Pub Date : 2024-02-22 Mohsin Ali, Melanie El Hafid, Daniel S. Farrar, Haifa Kourdi, Elizabeth Rea, Valerie Waters, Ray Lam, Shaun K. Morris, Ian Kitai
Extract In most low-burden settings, travel data is not routinely collected for tuberculosis (TB) case-notification and the quantitative contribution of travel to paediatric TB disease burden is unknown. The Hospital for Sick Children (SickKids) regional TB programme serves the Greater Toronto Area (GTA), Ontario, Canada, is closely integrated with GTA public health units, and manages most paediatric